Google DeepMind CEO Demis Hassabis says “AI-designed drugs could replace decades-long process,” outlines Isomorphic Labs vision
Google DeepMind CEO Demis Hassabis says AI-designed drugs could replace the decades-long drug discovery process. Isomorphic Labs aims to launch the first fully AI-designed drug trial by 2026.
Google DeepMind's Isomorphic Labs is working to speed up drug discovery using AI. The company aims to cut timelines and reduce failures in the process. AI models like AlphaFold 3 may be used to design drugs and predict their effects. Isomorphic Labs plans to launch the first clinical trial of a fully AI-designed drug by 2026. This development could revolutionize the field of medicine by making new treatments available more quickly.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.